> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Review Period Set for Bayer’s Adempas
- URL: https://www.fdaweb.com/review-period-set-for-bayers-adempas/
- Published: 2016-04-12T12:00:00.000Z
- Updated: 2026-09-14T20:54:13.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5135337

*Federal Register* Notice: FDA has determined the regulatory review period for Bayer’s Adempas (riociguat) is 2,394 days for extending a patent which claims the human drug product. Adempas is indicated for treating adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and treatment of pulmonary arterial hypertension to improve exercise capacity, improve WHO functional class, and to delay clinical worsening. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-04-12/pdf/2016-08337.pdf?ref=fdaweb.com)